Everest Organics share price, P/E, ROE & financials

As of 6 Nov 2026, Everest Organics trades at 44.3× trailing earnings, above the industry P/E of 28.7×, and the shares are 55% below their 52-week high. Sales grew 2.3% a year over 3 years, with ROCE of 16% and ROE of 7.6%. Debt is 0.66× equity. It is a small-cap company with a market cap of ₹238 Cr, ranked 90th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 38% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹243.50
Day high: ₹243.50
Day low: ₹235.00
Prev. close: ₹241.05
Volume: 16

Health check

2 fair · 4 to check

ReturnsBehind
−37.6% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 44.3 vs industry 28.7.
GrowthSlow
Sales +2.3% a year over 3 years.
ProfitabilityAverage
ROCE 15.8% vs peer median 17.9%.
Balance sheetFair
Debt 0.66× equity, interest covered 2.4×, Piotroski 7 of 9.
Red flags5 to check
Return on equity is low at 7.6%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹238 Cr, #90 of 154 in its industry by size.

Defensive

Beta 0.48 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹192 Cr · profit ₹5 Cr

Market cap: ₹238 Cr; Small cap
P/E: 44.3; Industry 28.7
Price to book: 3.10; Peers 4.99
Dividend yield: 0.00%
ROE: 7.6%; Peers 14.7%
ROCE: 15.8%; Peers 17.9%
Debt to equity: 0.66; Debt ₹50 Cr
EPS (TTM): ₹5.40
OPM (TTM): 10.3%; Net margin 2.7%
Sales growth: −10.0%; Latest quarter vs a year ago
Profit growth: −20.8%; Latest quarter vs a year ago
Price to sales: 1.24; EV/EBITDA 13.4

Risks to check

Return on equity is low at 7.6%.
Quarterly profit down 20.8% on a year ago.
Quarterly sales down 10.0% on a year ago.
P/E of 44.3 against an industry P/E of 28.7.
55% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Everest Organics

Everest Organics Limited engages in the manufacture and sale of active pharmaceutical ingredients and its intermediaries in India. It is also involved in the manufacturing of bulk drugs-related business. The company exports its products. Everest Organics Limited was incorporated in 1993 and is based in Hyderabad, India.

Headquarters: Hyderabad
Employees: 316
Sector: Healthcare
ISIN: INE334C01029
Website: everestorganicsltd.com

Price range

52 weeks

₹197.00₹536.40

Today

₹235.00₹243.50

Avg volume (3M): 1.4K
1-year return: minus 37.6%
From 52-week high: minus 55.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
EVERESTOEverest Organics	239.00	minus 0.85%	238	44.3	3.10	15.8%	7.6%	10.3%	2.3%	–	0.00%	minus 37.6%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
53.8	51	42.6	48.7	48.4
49.4	45.9	39.1	42	44.1
4.4	5.1	3.5	6.7	4.3
8.2%	10.1%	8.3%	13.7%	8.9%
0.5	0.3	0.2	0.2	0.4
1.3	1.2	1.2	2.8	1.6
1.5	1.5	1.5	1.9	1.6
2.2	2.7	1	2.2	1.5
35.1%	56.8%	65.7%	−21.1%	27.2%
1.4	1.2	0.4	2.6	1.1
1.45	1.19	0.37	2.69	1.15

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +2.3%
ROE: 7.6%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
183	197	159	196
–	+7.8%	minus 19.1%	+23.1%
181	186	151	175
1.8	11.7	8.4	21.2
1.0%	6.0%	5.2%	10.8%
0.7	−0.5	−0.5	−0.2
2.9	4.8	4.4	5.8
4.5	5.8	6	6.5
5.1	–	−0.7	−0.6
0.1	0.6	−3.2	8
302.7%	77.2%	60.2%	31.1%
−0.2	0.1	−1.3	5.5
-0.23	0.17	-2.97	5.70

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
8	8	9.7	9.7
38.2	37.8	60.2	65.8
52.2	58.1	47.9	49.9
103	123	106	114
202	227	223	240
64	72.3	70.3	66.6
9.5	19.9	22	22.7
0.1	0.1	0.1	0.1
0.8	0.8	6.6	0.6
127	134	124	150
202	227	223	240

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
18.4	16.1	−5.4	4.2
−16.1	−13	−5.2	−1.7
−2.6	−3.1	16.4	−8.4
−0.4	−0	5.8	−6
−13.5	−13.1	−5.4	−3.2
4.9	3	−10.8	0.9

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you